16. Crow-Fukase syndrome
12 clinical trials,   18 drugs   (DrugBank: 8 drugs),   5 drug target genes,   79 drug target pathways

Searched query = "Crow-Fukase syndrome", "POEMS syndrome", "Polyneuropathy, organomegaly, endocrinopathy, m-protein, and skin changes syndrome", "Takatsuki disease", "PEP syndrome", "Polyneuropathy, endocrinopathy, plasma cell dyscrasia syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02921893
(ClinicalTrials.gov)
October 31, 201626/9/2016Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeIxazomib, Lenalidomide, and Dexamethasone for Patients With POEMS SyndromePlasmacytoma;POEMS SyndromeDrug: Dexamethasone;Drug: Ixazomib Citrate;Other: Laboratory Biomarker Analysis;Drug: Lenalidomide;Other: Questionnaire AdministrationMayo ClinicNational Cancer Institute (NCI)Recruiting18 YearsN/AAll34Phase 2United States
2NCT01816620
(ClinicalTrials.gov)
March 201414/3/2013Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS SyndromeAn Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS SyndromePOEMS SyndromeDrug: Lenalidomide, DexamethasonePeking Union Medical College HospitalCelgene CorporationCompleted18 YearsN/AAll41Phase 2China
3NCT01639898
(ClinicalTrials.gov)
July 20125/7/2012POEMS Syndrome Treatment With LenalidomidePhase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.POEMS SyndromeDrug: Lenalidomide and dexamethasoneUniversity Hospital, LimogesMinistry of Health, France;Celgene CorporationCompleted18 YearsN/AAll51Phase 2France
4NCT00971685
(ClinicalTrials.gov)
July 20093/9/2009The Treatment of Lenalidomide in Patients With POEMS SyndromeEvaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS SyndromePOEMS SyndromeDrug: Lenalidomide and dexamethasoneIstituto Clinico HumanitasNULLRecruiting18 YearsN/ABoth16Phase 2Italy